A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.
Marc MiravitllesKatia M C VerhammePeter M A CalverleyMichael DreherValentina BayerAsparuh GardevAlberto de la HozJadwiga WedzichaDavid J PricePublished in: International journal of chronic obstructive pulmonary disease (2022)
This pooled analysis of over 6000 patients with mild-to-very-severe COPD and predominantly low exacerbation risk showed no differences in mortality with LAMA/LABA versus LAMA/LABA/ICS, suggesting that the survival benefit of triple therapy seen in some recent studies may be specific to a high-risk population. This supports current Global Initiative for Chronic Obstructive Lung Disease recommendations that triple therapy should be reserved for the subpopulations of patients who need it the most (eg, those with an eosinophilic phenotype and a high risk of exacerbations) to avoid ICS overuse.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- cystic fibrosis
- cardiovascular events
- risk factors
- muscular dystrophy
- quality improvement
- clinical trial
- early onset
- stem cells
- cardiovascular disease
- clinical practice
- type diabetes
- bone marrow
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- case control
- chronic rhinosinusitis
- breast cancer risk